-+ 0.00%
-+ 0.00%
-+ 0.00%

Sight Sciences TearCare wins FDA label expansion to improve meibomian gland function in dry eye patients

PUBT·08/19/2026 11:06:12
Listen to the news
Sight Sciences TearCare wins FDA label expansion to improve meibomian gland function in dry eye patients
  • FDA updated the TearCare System indication effective Aug. 18, 2026 to include improving meibomian gland function in adult evaporative dry eye.
  • Label now specifies use with manual meibomian gland expression; optional debridement added as part of the cleared system.
  • Change expands the product’s permitted marketing claims, potentially strengthening reimbursement and competitive positioning in MGD treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sight Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608190705PRIMZONEFULLFEED9812581) on August 19, 2026, and is solely responsible for the information contained therein.